0001209191-18-035400.txt : 20180604
0001209191-18-035400.hdr.sgml : 20180604
20180604205115
ACCESSION NUMBER: 0001209191-18-035400
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180523
FILED AS OF DATE: 20180604
DATE AS OF CHANGE: 20180604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HESTERBERG LYNDAL K.
CENTRAL INDEX KEY: 0001689836
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 18879885
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoCyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 510-775-0515
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-23
0
0001642380
OncoCyte Corp
OCX
0001689836
HESTERBERG LYNDAL K.
1010 ATLANTIC AVENUE
SUITE 102
ALAMEDA
CA
94501
0
1
0
0
Sr VP, Research & Development
Option to Purchase Common Stock
2.35
2018-05-23
4
A
0
150000
0.00
A
2028-05-22
Common Stock
150000
150000
D
Option to Purchase Common Stock
4.70
2027-02-16
Common Stock
14400
14400
D
Option to Purchase Common Stock
4.05
2026-10-31
Common Stock
125000
125000
D
Option to Purchase Common Stock
3.06
2026-02-15
Common Stock
25000
25000
D
These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
One quarter of the options vested on October 31, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
One quarter of the options vested on February 15, 2017 and one quarter vested on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.
/s/Lyndal K. Hesterberg
2018-06-01